SAID ALIZADA | AVESİS

Akademik Veri Yönetim Sistemi

Yayınlar & Eserler

Makaleler 5

1. Prognostic significance of oligoclonal bands and their subtypes in relapsing-remitting multiple sclerosis

Ozakbas P. S., Alizada S., Cevik S., Samadzade U., Yapici N. A., Zengin E. S., et al.

Multiple Sclerosis and Related Disorders , cilt.104, 2025 (SCI-Expanded)

2. Revisiting the diagnostic marker: Oligoclonal band positivity is not associated with early disability or cognitive performance in relapsing-remitting multiple sclerosis

Samadzade U., ALIZADA S., Zengin E. S., Çevik S., Yapıcı N., Kara İ., et al.

MULTIPLE SCLEROSIS AND RELATED DISORDERS , cilt.104, 2025 (SCI-Expanded, Scopus)

3. Familial multiple sclerosis is associated with accelerated progression to secondary progressive phase: a retrospective single-center cohort study

Ozakbaş S., Alızada S., Caliskan C., Simsek Y., Zengin E. S.

DEUTSCHE ZEITSCHRIFT FUR NERVENHEILKUNDE , cilt.272, sa.12, 2025 (SCI-Expanded, Scopus)

4. Pediatric-onset Multiple Sclerosis in Families: A Distinct Phenotype

Alızada S., Caliskan C., Zengin E. S., Simsek Y.

Journal of Multiple Sclerosis Research , cilt.5, sa.2, ss.52-56, 2025 (Hakemli Dergi)

5. Can the Age of the First Symptom of Neuromyelitis Optica be Used to Predict Cognitive Impairment?

Unal G. D., Alızada S., Kara I., Calıskan C., Samadzade U., Zengin E. S.

Journal of Multiple Sclerosis Research , cilt.4, sa.1, ss.3-7, 2025 (Hakemli Dergi)

Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 31

1. Ten-Year Long-Term Efficacy of Fingolimod in Relapsing Multiple Sclerosis: Sustained Disease Control and Relapse Prevention in Long-Term Users

Ozakbas S., Alızada S., Caliskan C., Samadzade U.

Congress of the European Committee for Treatment and Research in Multiple Sclerosis 2025, Barcelona, İspanya, 24 - 26 Eylül 2025, (Özet Bildiri)

2. Children of Parents with Multiple Sclerosis: A Health and Psychosocial Profile

Şimşek Y., Caliskan C., Alızada S., Ozakbas S.

Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Barcelona, İspanya, 24 - 26 Eylül 2025, (Özet Bildiri)

3. Five-Year Real-World Outcomes of Fingolimod in Multiple Sclerosis: Long-Term Effectiveness and Treatment Continuation Patterns

Ozakbas S., Alızada S., Samadzade U., Caliskan C.

Congress of the European Committee for Treatment and Research in Multiple Sclerosis 2025, Barcelona, İspanya, 24 - 26 Eylül 2025, (Özet Bildiri)

4. Prevalence and Impact of Pain on Quality of Life in a Large Multiple Sclerosis Cohort: A Cross-Sectional Study

Alızada S., Ozdogar A. T., Kara İ., Kahraman T., Ozakbas S.

Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Barcelona, İspanya, 24 - 26 Eylül 2025, (Özet Bildiri)

5. Longitudinal Impact of Fingolimod on Disease Course in Multiple Sclerosis: A Three-Year Pre- and Post-Treatment Analysis

Alızada S., Samadzade U., Caliskan C., Mammadov O., Ozakbas S.

Congress of the European Committee for Treatment and Research in Multiple Sclerosis 2025, Barcelona, İspanya, 24 - 26 Eylül 2025, (Özet Bildiri)

6. Five Years of Ocrelizumab in MS: Clinical Stability and Subtle Cognitive Gains

Ozakbas S., Samadzade U., Ünal G. D., Caliskan C., Kara İ., Alızada S.

Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Barcelona, İspanya, 24 - 26 Eylül 2025, (Özet Bildiri)

7. Six-Year Disease Trajectory in Multiple Sclerosis: A Pre- and Post-Ocrelizumab Treatment Analysis

Samadzade U., Alızada S., Caliskan C., Mammadov O., Kara İ., Ozakbas S.

Congress of the European Committee for Treatment and Research in Multiple Sclerosis 2025, Barcelona, İspanya, 24 - 26 Eylül 2025, (Özet Bildiri)

8. Impact of Chronic Pain on Cognitive Reserve in Multiple Sclerosis

Özdoğar A. T., Kahraman T., Alızada S., Ozakbas S.

Congress of the European Committee for Treatment and Research in Multiple Sclerosis 2025, Barcelona, İspanya, 24 - 26 Eylül 2025, (Özet Bildiri)

9. Cognitive Profiles of Relapsing Multiple Sclerosis Patients with Progression Independent of Relapse Activity Versus Non-NEDA-3 Status

Alızada S., Ozdogar A. T., Samadzade U., Caliskan C., Ozakbas S.

Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Barcelona, İspanya, 24 - 26 Eylül 2025, (Özet Bildiri)

10. The Migraine Screen Questionnaire (MS-Q): A Valid Tool for Identifying Migraine in Persons with Multiple Sclerosis

Alızada S., Caliskan C., Kahraman T., Ozakbas S.

Congress of the European Committee for Treatment and Research in Multiple Sclerosis 2025, Barcelona, İspanya, 24 - 26 Eylül 2025, (Özet Bildiri)

11. Pregnancy and Disease Activity in Neuromyelitis Optica Spectrum Disorder: A Retrospective Study of Relapse Burden and Disability Progression

Caliskan C., Şimşek Y., Alızada S., Zengin E. S., Ozakbas S.

41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Barcelona, İspanya, 24 - 26 Eylül 2025, (Özet Bildiri)

12. Sustained Effectiveness or Inevitable Discontinuation? Five-Year Real-World Outcomes of Teriflunomide Therapy in Multiple Sclerosis

Ozakbas S., Alızada S., Samadzade U., Caliskan C.

Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Barcelona, İspanya, 24 - 26 Eylül 2025, (Özet Bildiri)

13. Predictors of disability progression in multiple sclerosis patients: A retrospective analysis

Samadzada U., Ozdogar A. T., Unal G. D., Kara I., Alızada S., Ozakbas S.

11th Congress of the European Academy of Neurology, Helsinki, Finlandiya, 21 - 24 Haziran 2025, ss.747, (Özet Bildiri)

14. Five-year outcomes in MS patients based on Type 2 and Type 3 oligoclonal band patterns

Alızada S., Samadzade U., Yapici N., Cevik S., Zengin E. S., Ozakbas S.

11th Congress of the European Academy of Neurology, Helsinki, Finlandiya, 21 - 24 Haziran 2025, ss.279, (Özet Bildiri)

15. Understanding Factors Influencing Deterioration in Upper and Lower Extremity Outcomes in Multiple Sclerosis

Alızada S., Ozdogar A. T., Ünal G. D., Kara İ., Yapici N. A., Ozakbas S.

AAN Annual Meeting 2025, California, Amerika Birleşik Devletleri, 5 - 09 Nisan 2025, (Özet Bildiri)

16. Impact of Oligoclonal Band Status on Initial Clinical Presentation and Progression in Relapsing-remitting Multiple Sclerosis

Alızada S., Samadzade U., Yapici N., Cevik S., Zengin E. S., Ozakbas S.

AAN Annual Meeting 2025, California, Amerika Birleşik Devletleri, 5 - 09 Nisan 2025, (Özet Bildiri)

17. Associating Age of Symptom Onset with Cognitive Impairment Severity in Multiple Sclerosis: A Comparative Study

Ozakbas S., Unal G. D., ALIZADA S., Kara I., Simsek Y.

10th Annual Meeting of the International-MS-Cognition-Society (IMSCOGS), Bern, İsviçre, 2 - 03 Eylül 2024, sa.3, (Özet Bildiri)

18. Familial Multiple Sclerosis: Unveiling Disease Progression and Clinical Correlates

Simsek Y., ALIZADA S., Caliskan C., Ozakbas S.

40th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Copenhagen, Danimarka, 18 - 20 Eylül 2024, sa.3, ss.1248, (Özet Bildiri)

19. Can the age of the first symptom for neuromyelitis optica be used to predict cognitive impairment?

Unal G. D., ALIZADA S., Kara I., Simsek Y., Ozakbas S.

40th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Copenhagen, Danimarka, 18 - 20 Eylül 2024, sa.3, ss.725-726, (Özet Bildiri)

20. The Oligoclonal Band Dilemma: Decoding its Role in Predicting Relapsing-Remitting Multiple Sclerosis Progression

Baba C., ALIZADA S., Samadzade U., Cevik S., Yapici N., Simsek Y., et al.

40th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Copenhagen, Danimarka, 18 - 20 Eylül 2024, cilt.30, sa.3, ss.1207, (Özet Bildiri)

21. Enhancing Disability Progression Assessment in Multiple Sclerosis: Introducing the EDSS-Plus Score

Ozcelik S., Özdoğar A. T., ALIZADA S., Cinar B. P., Ozakbas S.

40th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Copenhagen, Danimarka, 18 - 20 Eylül 2024, ss.471-472, (Özet Bildiri)

22. Determinants of Postpartum Relapse in Multiple Sclerosis: A Comprehensive Analysis of Demographic and Clinical Factors

ALIZADA S., Samadzade U., Yapici N., KAYA E., Özdoğar A. T., Ozakbas S.

40th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Copenhagen, Danimarka, 18 - 20 Eylül 2024, cilt.30, sa.3, ss.196-197, (Özet Bildiri)

23. Evaluating the Effectiveness of No Evidence of Disease Activity-3 in Managing Progression Independent of Relapse Activity and Relapse-Associated Worsening in Multiple Sclerosis

Ozcelik S., Özdoğar A. T., ALIZADA S., Ozakbas S.

40th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Copenhagen, Danimarka, 18 - 20 Eylül 2024, ss.1158, (Özet Bildiri)

24. Use of High-Efficacy Therapies of Early- and Late-Onset Multiple Sclerosis Compared to Adult-Onset Multiple Sclerosis

Ozakbas S., Aslan T., KAYA E., ALIZADA S., Özdoğar A. T.

40th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Copenhagen, Danimarka, 18 - 20 Eylül 2024, sa.3, ss.1026, (Özet Bildiri)

25. Determinants of Fatigue in People with Multiple Sclerosis: An Investigative Analysis

Özdoğar A. T., ALIZADA S., Simsek Y., Ozakbas S.

40th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Copenhagen, Danimarka, 18 - 20 Eylül 2024, sa.3, ss.746, (Özet Bildiri)

26. Clinical Comparison of Early and Late Onset Multiple Sclerosis at Age 35: Implications for Disease Progression and Management

KAYA E., Aslan T., Özdoğar A. T., ALIZADA S., Ozakbas S.

40th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Copenhagen, Danimarka, 18 - 20 Eylül 2024, sa.3, ss.769, (Özet Bildiri)

27. Unraveling the Genetic Threads: Exploring Familial Dynamics and Clinical Profiles in Pediatric-Onset Multiple Sclerosis

Simsek Y., Caliskan C., ALIZADA S., Ozakbas S.

40th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Copenhagen, Danimarka, 18 - 20 Eylül 2024, sa.3, ss.1209-1210, (Özet Bildiri)

28. Prevalence of Various Cancer Types Among Multiple Sclerosis Patients: Insights from a Retrospective Analysis

ALIZADA S., Simsek Y., Ozakbas S.

40th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Copenhagen, Danimarka, 18 - 20 Eylül 2024, sa.3, ss.834, (Özet Bildiri)

29. Imaging and laboratory characteristics of case series diagnosed with probable sporadic Creutzfeldt-Jakob disease

Fırat A., Alızada S., Çakmur R., Öztura İ., Karabay N., Öz D.

10th Congress of the European Academy of Neurology, Helsinki, Finlandiya, 28 Haziran - 02 Temmuz 2024, ss.800, (Özet Bildiri)

Creative Commons License

30. Impairment based aphasia therapy: impact on grammar in patients with post stroke non-fluent aphasia

Alızada S., Özcan Vural A., Öztürk V., Kuruoğlu G.

10th Congress of the European Academy of Neurology, Helsinki, Finlandiya, 28 Haziran - 02 Temmuz 2024, cilt.31, sa.1, ss.800, (Özet Bildiri)

Creative Commons License

31. Effects of two grams of methylprednisolone in people with multiple sclerosis who received one gram of methylprednisolone for relapses

Alızada S., Özçelik S., Dastan S., Sagici O., Özdoğar A. T., Ozakbas S.

9th Joint ECTRIMS-ACTRIMS meeting, Milan, İtalya, 11 - 13 Ekim 2023, ss.1040, (Özet Bildiri)

Creative Commons License

Kitaplar 1

1. Tik ile gelen hastada tanısal yaklaşım ve tedavi ilkeleri

Alızada S., Yener G.

Hipekinetik Hareket Bozukluklarında Güncel Tanı ve Tedavi Yaklaşımı, Said Alizada,Görsev Yener, Editör, Türkiye Klinikleri Yayınevi, Ankara, ss.50-55, 2024

Metrikler

Yayın

53

Yayın (WoS)

16

Yayın (Scopus)

3

Açık Erişim

9